



NEWS RELEASE

Revvity Unveils a New Era of Automated Tuberculosis Testing

4/24/2024

- New and improved workflow now available that pairs Revvity's T-SPOT™.TB test with the Auto-Pure 2400 liquid handling platform
- Substantially lowers hands-on time, allowing for increased lab productivity

WALTHAM, Mass.--(BUSINESS WIRE)-- **Revvity, Inc.** (NYSE: RVTY) today announced the launch of the **Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test**. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution.

"The ability to use the Auto-Pure 2400 platform with our T-SPOT.TB test provides labs an efficient workflow allowing latent TB testing to be run in a mid-high-volume setting, without having to compromise on the clinical performance of the test," said Darren Sher, general manager, infectious diseases for Revvity. "With this solution, more labs can offer clinicians access to the most accurate TB diagnostic on the market."

Auto-Pure 2400 liquid handler for use with the T-SPOT.TB test

- The Auto-Pure 2400 automated liquid handling platform is equipped with integrated magnetic cell isolation technology.
- Designed for testing up to 24 samples per run, it completes day-1 T-SPOT.TB workflows in under 3.5 hours, requiring only a single mid-run user interaction.
- The solution not only simplifies lab workflows but also boasts an intuitive software user interface.

About the T-SPOT.TB test

- The T-SPOT.TB test detects latent tuberculosis infection (LTBI) and is an interferon-gamma release assay (IGRA) based on the enzyme-linked immunospot (ELISPOT) technology.
- This technology has crucial steps that the World Health Organization has recently recognized as critical in ensuring reliable and accurate TB test results. These steps include washing, isolating, and counting peripheral blood mononuclear cells (PBMCs) before conducting the test.

Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than \$2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our [Newsroom](#), [LinkedIn](#), [X](#), [YouTube](#), [Facebook](#) and [Instagram](#).

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Media Contact:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity